Reading Time: 1 minute
Axsome Therapeutics (AXSM) has good chances of a successful trend continuation with two pivotal news points since the beginning of the year. I am impressed by the strong pipeline of the specialist in the treatment of central nervous system (CNS) disorders, with a peak sales potential of over $16 billion. The core product Auvelity (AXS-05) remains in demand as an antidepressant and, due to a patent dispute won against Teva Pharmaceuticals, will not face pressure from generics before 2038. On December 31, the FDA announced an accelerated approval...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
